Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology
- PMID: 26839185
- PMCID: PMC4964647
- DOI: 10.1080/21645515.2015.1110658
Identification of potential missed opportunities for human papillomavirus (HPV) vaccination in women referred to an academic colposcopy clinic for evaluation of abnormal cervical cytology
Abstract
Objective: To identify possible predictors of missed opportunities for human papillomavirus (HPV) counseling and vaccination prior to presentation at an academic colposcopy clinic.
Materials and methods: We examined the characteristics of 638 vaccinated and 1,024 unvaccinated age-eligible patients using data from a patient registry of women presenting for colposcopic evaluation between 2/26/2007 and 3/10/2014 who were aged 26 or less at presentation. Demographics, smoking history, pregnancy history, sexually transmitted infections (STIs), sexual history, contraception use, immunosuppression, and medical problems were compared between HPV vaccinated and unvaccinated women. Multivariable logistic regression models included age, race, language, marital status, insurance type, lifetime number of sexual partners, other medical illnesses, number of pregnancies, contraception use, history of STIs, and smoking history to determine predictors of HPV vaccination.
Results: In multivariable analysis, race, marital status, and language were not significantly associated with HPV vaccination. Women with fewer pregnancies were more likely to be vaccinated (p-trend <0 .0001). Vaccinated women were more likely to have other medical illnesses (OR=1.44, 95% CI=1.13-1.83) and be aware of their HPV status (OR=1.75, 95% CI= 1.40-2.18).
Conclusions: In this study, greater number of pregnancies was associated with lower vaccination rates as compared to women who had never been pregnant. Reproductive health visits, such as postpartum and family planning visits, represent an ideal opportunity to educate women about HPV and the importance of vaccination, and should be an area of focus to improve current HPV vaccination rates.
Keywords: abnormal cervical cytology; cervical cancer; colposcopy; human papillomavirus vaccination; provider counseling.
Similar articles
-
Comparing Cervical Cytology and Histology Among Human Papillomavirus-Vaccinated and -Unvaccinated Women in an Academic Colposcopy Clinic.Obstet Gynecol. 2015 Oct;126(4):785-791. doi: 10.1097/AOG.0000000000001011. Obstet Gynecol. 2015. PMID: 26348184
-
Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus Vaccination.JAMA Netw Open. 2022 May 2;5(5):e2214020. doi: 10.1001/jamanetworkopen.2022.14020. JAMA Netw Open. 2022. PMID: 35612854 Free PMC article.
-
Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.Vaccine. 2012 Jul 27;30(35):5215-21. doi: 10.1016/j.vaccine.2012.06.013. Epub 2012 Jun 17. Vaccine. 2012. PMID: 22713720
-
HPV testing and vaccination in Europe.J Low Genit Tract Dis. 2014 Jan;18(1):61-9. doi: 10.1097/LGT.0b013e318286b8d3. J Low Genit Tract Dis. 2014. PMID: 23774078 Review.
-
Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening.Vaccine. 2007 Apr 20;25(16):3007-13. doi: 10.1016/j.vaccine.2007.01.016. Epub 2007 Jan 18. Vaccine. 2007. PMID: 17292517 Review.
Cited by
-
Evaluating the impact of multilevel evidence-based implementation strategies to enhance provider recommendation on human papillomavirus vaccination rates among an empaneled primary care patient population: a study protocol for a stepped-wedge cluster randomized trial.Implement Sci. 2018 Jul 13;13(1):96. doi: 10.1186/s13012-018-0778-x. Implement Sci. 2018. PMID: 30001723 Free PMC article. Clinical Trial.
References
-
- American Cancer Society Cancer Facts & Figures. Atlanta, Ga: American Cancer Society; 2015.
-
- Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsaque X, Shah KV, Snijders PJF, Meijer CJLM. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518–27; PMID:12571259; http://dx.doi.org/10.1056/NEJMoa021641 - DOI - PubMed
-
- Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, et al.. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301–14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4 - DOI - PubMed
-
- Future II Study Group . Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915–27; PMID:17494925; http://dx.doi.org/10.1056/NEJMoa061741 - DOI - PubMed
-
- Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, et al.. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356:1928–43; PMID:17494926; http://dx.doi.org/10.1056/NEJMoa061760 - DOI - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical